Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Lheureux

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
International Journal of Molecular Sciences|May 13, 2026
Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed AssayScott Strum, Clodagh Murray, Sofia Genta, et al.
Cancer Treatment and Research Communications|June 1, 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)Helen J MacKay, Anna V Tinker, Brad H Nelson, et al.
Gynecologic Oncology|September 11, 2020
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancerAinhoa Madariaga, Swati Garg, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
JNCI Cancer Spectrum|February 8, 2021
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisMarco A J Iafolla, Cindy Yang, Vinod Chandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase InhibitionStephanie Lheureux, Jeff P Bruce, Julia V Burnier, et al.
American Journal of Obstetrics and Gynecology|June 26, 2021
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferencesAinhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2022
Interobserver and intraobserver variability of RECIST assessment in ovarian cancerMichael Krasovitsky, Yeh Chen Lee, Hao-Wen Sim, et al.
Journal of Nursing Care Quality|October 10, 2022
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic CancerNazlin Jivraj, Yeh Chen Lee, Lisa Tinker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 28, 2023
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancersEduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
International Journal of Molecular Sciences|May 13, 2026
Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed AssayScott Strum, Clodagh Murray, Sofia Genta, et al.
Cancer Treatment and Research Communications|June 1, 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)Helen J MacKay, Anna V Tinker, Brad H Nelson, et al.
Gynecologic Oncology|September 11, 2020
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancerAinhoa Madariaga, Swati Garg, Jeffrey P Bruce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
JNCI Cancer Spectrum|February 8, 2021
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisMarco A J Iafolla, Cindy Yang, Vinod Chandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase InhibitionStephanie Lheureux, Jeff P Bruce, Julia V Burnier, et al.
American Journal of Obstetrics and Gynecology|June 26, 2021
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferencesAinhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2022
Interobserver and intraobserver variability of RECIST assessment in ovarian cancerMichael Krasovitsky, Yeh Chen Lee, Hao-Wen Sim, et al.
Journal of Nursing Care Quality|October 10, 2022
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic CancerNazlin Jivraj, Yeh Chen Lee, Lisa Tinker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 28, 2023
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancersEduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, et al.
Pageof 14